Device Trial Radar · NCT01110681
Study to Evaluate Solesta for Treatment of Fecal Incontinence
Last checked: Nov 19, 2026Latest source record: Aug 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
115
Actual
Start
Nov 2007
Primary completion
Nov 2009
Study completion Dec 2010
Sponsor
- Lead sponsor
- Galderma R&DNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 27, 2010
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the safety and efficacy of Solesta as an injectable bulking agent in the treatment of fecal incontinence for a total of 24 months after completed treatment.
Conditions
- Fecal Incontinence
Interventions
Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Responder Rate in Number of Fecal Incontinence EpisodesTime frame: 12 months after last treatment compared to baseline
Locations
15 sites in 7 countries. Site status is shown where the registry gives one.
St. Paul's Hospital
Vancouver, Canada
Helsingin yliopistollinen keskussairaala
HUS, Finland
CHU-Hotel-Dieu
Nantes, France
12 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.